Distinguished in Posterior Fossa Tumor

Dr. Jiayi W. Huang

Radiation Oncology
Washington University
4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
Accepting New Patients
Distinguished in Posterior Fossa Tumor
Washington University
4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jiayi Huang is a Radiation Oncologist in Saint Louis, Missouri. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Astrocytoma, Glioblastoma, Meningioma, Tissue Biopsy, and Gamma Knife Radiosurgery. Dr. Huang is currently accepting new patients.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Posterior Fossa Tumor.

Specialties
Radiation Oncology
Licenses
Radiology in MO
Hospital Affiliations
Barnes Jewish Hospital
Christian Hospital Northeast
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Lowr Lvl, Saint Louis, MO 63110
Other Locations
WASHINGTON UNIVERSITY
5225 Mid America Plz, Saint Louis, MO 63129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Radiation
Study Drugs: rhIL-7-hyFc, Temozolomide
Study Phase: Phase 1/Phase 2
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug, Radiation
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Disulfiram, Copper Gluconate, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Radiation, Drug, Procedure
Study Drug: Avelumab
Study Phase: Phase 1
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drug: Tadalafil
Study Phase: Phase 1
Feasibility and Safety of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Feasibility and Safety of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Device, Drug, Other
Study Phase: Phase 1
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 19, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: November 17, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 15 Less Clinical Trials
Similar Doctors
Distinguished in Posterior Fossa Tumor
Dr. Clifford G. Robinson
Radiation Oncology
Distinguished in Posterior Fossa Tumor
Dr. Clifford G. Robinson
Radiation Oncology

Washington University

4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-9715
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Clifford Robinson is a Radiation Oncologist in Saint Louis, Missouri. Dr. Robinson is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Robinson is currently accepting new patients.

Distinguished in Posterior Fossa Tumor
Dr. Pawel T. Dyk
Radiation Oncology
Distinguished in Posterior Fossa Tumor
Dr. Pawel T. Dyk
Radiation Oncology

Missouri Baptist Physician Services LLC

3015 N Ballas Rd, 
Saint Louis, MO 
 (10.0 miles away)
314-996-5544
Experience:
17+ years
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients

Pawel Dyk is a Radiation Oncologist in Saint Louis, Missouri. Dr. Dyk has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Penile Cancer. Dr. Dyk is currently accepting new patients.

Distinguished in Posterior Fossa Tumor
Dr. Vincent Q. Joe
Radiation Oncology | Radiology
Distinguished in Posterior Fossa Tumor
Dr. Vincent Q. Joe
Radiation Oncology | Radiology

Missouri Baptist Physician Services LLC

3015 N Ballas Rd, 
Saint Louis, MO 
 (10.0 miles away)
314-996-5544
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vincent Joe is a Radiation Oncologist and a Radiologist in Saint Louis, Missouri. Dr. Joe is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Small Cell Lung Cancer (SCLC). Dr. Joe is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huang's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 13 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile